Dror Bashan insider trades: Protalix BioTherapeutics (PLX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Dror reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | PLX | ↑ Buy | 56,000 | $1.81 | $101K | Direct | Dec 23, 2025 (4d) |
| Oct 19, 2023 | PLX | ↑ Buy | 64,516 | $1.40 | $90K | Direct | Oct 20, 2023 (1d) |
| Apr 11, 2022 | PLX | ↑ Buy | 68,000 | $1.50 | $102K | Direct | Apr 13, 2022 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PLX insiders
Open-market trades in the last 12 months
About Dror Bashan's insider trades
Dror Bashan is President and CEO at Protalix BioTherapeutics (PLX). Since Apr 11, 2022, Dror has reported 3 open-market purchases worth $294K and no sales on SEC Form 4. In the last 12 months: 1 buy ($101K).
Their filings also include grants and awards (8 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PLX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.